CN108676078A - 引起坦布苏病毒抗体依赖增强作用的抗原的应用 - Google Patents
引起坦布苏病毒抗体依赖增强作用的抗原的应用 Download PDFInfo
- Publication number
- CN108676078A CN108676078A CN201810499820.8A CN201810499820A CN108676078A CN 108676078 A CN108676078 A CN 108676078A CN 201810499820 A CN201810499820 A CN 201810499820A CN 108676078 A CN108676078 A CN 108676078A
- Authority
- CN
- China
- Prior art keywords
- virus
- antigen
- antibody
- tambusu
- dependent enhancement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 36
- 108091007433 antigens Proteins 0.000 title claims abstract description 36
- 102000036639 antigens Human genes 0.000 title claims abstract description 36
- 241000907504 Tembusu virus Species 0.000 title claims abstract description 20
- 241000700605 Viruses Species 0.000 claims abstract description 38
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 17
- 229960005486 vaccine Drugs 0.000 claims abstract description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 239000004744 fabric Substances 0.000 claims 2
- 229960004854 viral vaccine Drugs 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 abstract description 28
- 102000004169 proteins and genes Human genes 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 5
- 230000005727 virus proliferation Effects 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 230000001681 protective effect Effects 0.000 abstract description 4
- 241000588724 Escherichia coli Species 0.000 abstract description 3
- 238000013461 design Methods 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 238000012827 research and development Methods 0.000 abstract description 2
- 230000003053 immunization Effects 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 4
- 241000710831 Flavivirus Species 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 206010058874 Viraemia Diseases 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 241000272525 Anas platyrhynchos Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241001529459 Enterovirus A71 Species 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 241000907316 Zika virus Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
- G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
Abstract
本发明公开了引起坦布苏病毒抗体依赖增强作用的抗原的应用。所述的引起坦布苏病毒抗体依赖增强作用的抗原，其氨基酸序列如SEQ ID NO.1所示。本发明所述的引起坦布苏病毒抗体依赖增强作用的抗原在制备坦布苏病毒疫苗中的应用。本发明用大肠杆菌表达的上述表位蛋白免疫雏鸭，可在雏鸭体内诱导产生高水平特异性抗体，该抗体可促进病毒增殖，提高病毒在雏鸭体内的滴度。在未来坦布苏病毒疫苗研发中，可通过分子设计去除该类抗原，避免疫苗引起抗体依赖增强作用，保证保护效果，因此，鉴定引起坦布苏病毒抗体依赖增强作用的抗原对研制有效、安全的疫苗和防控坦布苏病毒的流行具有重要的应用价值。
Description
技术领域
本发明属于分子生物学和免疫学技术领域，涉及引起坦布苏病毒抗体依赖增强作用的抗原的应用。
背景技术
坦布苏病毒病是一种以食欲急剧减退、产蛋量骤降为主要特征的新发疫病，给鸭鹅养殖业造成了重大经济损失，引发该病的坦布苏病毒属于黄病毒科、黄病毒属，该属病毒包括登革病毒、日本脑炎病毒、西尼罗病毒、黄热病毒、寨卡病毒等虫媒病毒。
病毒通过表面蛋白黏附于宿主细胞上的特异性受体起始感染过程。病毒表面蛋白的特异性抗体可以通过封闭表面蛋白阻抑病毒与受体的黏附，将病毒“中和”，使其失去感染细胞的能力。然而在有些情况下，抗体在病毒感染过程中却发挥相反的作用。它们协助病毒进入靶细胞，提高感染率，这一现象称为抗体依赖增强作用。目前，在多个科属的病毒中发现了抗体依赖增强作用现象，包括黄病毒、肠道病毒71型、埃博拉病毒、流感病毒等。坦布苏病毒属于黄病毒，在临床上同样观察到抗体依赖增强作用，可导致病毒的持续感染和持久的病毒血症。
坦布苏病毒病发病急，传播迅速，感染率高，临床上较难控制。目前市场上有商品化的全病毒灭活疫苗和弱毒疫苗，免疫后可诱发高水平抗体，产生保护性免疫应答。但是，由于坦布苏病毒存在抗体依赖增强作用，疫苗免疫后的保护效果并不理想，存在二次感染后促进病毒增殖、增强致病性的隐患。因此，鉴定引起坦布苏病毒抗体依赖增强作用的抗原在疫苗研发中具有重要作用，可通过分子设计去除该类抗原，避免出现抗体依赖增强作用，确保疫苗免疫效果，对坦布苏病毒病的防控具有重要意义。
发明内容
本发明的目的是针对现有技术的上述不足，提供了一种引起坦布苏病毒抗体依赖增强作用的抗原及其编码基因。
本发明的目的可通过以下技术方案实现：
一种引起坦布苏病毒抗体依赖增强作用的抗原，其氨基酸序列为482-SMTFLAVGGILVFLA-496(SEQ ID NO.1)。
编码本发明所述的引起坦布苏病毒抗体依赖增强作用的抗原的基因。
所述的基因其核苷酸序列如SEQ ID NO.2所示。
本发明所述的引起坦布苏病毒抗体依赖增强作用的抗原在制备坦布苏病毒疫苗中的应用。
本发明所述的引起坦布苏病毒抗体依赖增强作用的抗原在制备坦布苏病毒检测试剂中的应用。
本发明所述的引起坦布苏病毒抗体依赖增强作用的抗原编码基因在制备坦布苏病毒疫苗中的应用。
本发明所述的引起坦布苏病毒抗体依赖增强作用的抗原编码基因在制备坦布苏病毒检测试剂中的应用。
制备本发明所述抗原的方法，通过人工直接合成或通过体外表达获得。例如通过含有在适当的转录启动子控制下的编码所需肽的重组核酸分子的微生物表达肽，以及从所属微生物收集所需肽。
有益效果：
本发明首次鉴定了一个引起坦布苏病毒抗体依赖增强作用的抗原，其氨基酸序列为482-SMTFLAVGGILVFLA-496。本发明用大肠杆菌表达的抗原免疫雏鸭，诱导产生特异性抗体，在雏鸭受到坦布苏病毒攻击后，该抗原的抗体可促进坦布苏病毒增殖，显著升高攻毒雏鸭体内病毒含量，导致产生持久的病毒血症。
本发明提供的抗原可诱导特异性抗体，在坦布苏病毒感染过程中，促进病毒增殖，引起抗体依赖增强作用。基于该发现，在未来坦布苏病毒疫苗研发中，可通过分子设计去除该类抗原，避免疫苗引起抗体依赖增强作用，保证保护效果，因此，鉴定引起坦布苏病毒抗体依赖增强作用的抗原对研制有效、安全的疫苗和防控坦布苏病毒的流行具有重要的应用价值。
附图说明
图1引起坦布苏病毒抗体依赖增强作用的抗原纯化的Western blot鉴定
图2引起坦布苏病毒抗体依赖增强作用的抗原对病毒增殖的促进作用
具体实施方式
实施例1引起坦布苏病毒抗体依赖增强作用的抗原的获得
根据引起坦布苏病毒抗体依赖增强作用的抗原的编码基因序列，采用人工合成方法获得编码基因片段，通过EcoR I和Sal I酶切位点插入到质粒pGEX-4t-1中得到重组质粒pGEX-4t-28。将表达载体pGEX-4t-28导入大肠杆菌中，得到表达抗原的工程菌株。将得到的工程菌株接种LB培养基，待OD600nm为0.4-0.6时加入终浓度为1mmol/L的IPTG对含有表达载体pGEX-4t-B的工程菌进行蛋白的诱导表达。表达产物采用Glutathione-agarose(Sigma)进行纯化，操作步骤按照说明书进行。得到纯化的抗原进行Western blot鉴定，结果显示得到目的蛋白(图1)。
实施例2引起坦布苏病毒抗体依赖增强作用的抗原诱导产生特异性抗体
1、将实施例1获得的抗原蛋白免疫9日龄雏鸭，每只200μg，首次免疫用等体积弗氏完全佐剂乳化。免疫2周后进行加强免疫一次，每只200μg，加强免疫用等体积弗氏不完全佐剂佐剂乳化。对照组雏鸭免疫相同体积的PBS，其余处理相同。
2、加强免疫后2周，对免疫组和对照组雏鸭进行翅静脉采血，分离血清，通过间接ELISA检测特异性抗体效价。
实施结果：免疫组雏鸭血清中特异性抗体效价均高于1:6400，而对照组雏鸭血清中特异性抗体效价均为阴性，说明抗原蛋白具有良好的免疫原性，可诱导雏鸭产生高水平特异性抗体。
实施例3抗原特异性抗体在体内对病毒增殖的促进作用
1、将实施例2中加强免疫2周后的雏鸭进行坦布苏病毒攻毒试验。每只的攻毒剂量为104TCID50。
2、攻毒后1-5天，每天无菌采集雏鸭翅静脉血，分离血清，接种已长成单层的BHK-21细胞。37℃孵育2h后，PBS洗涤3次，加入含1％胎牛血清的RPMI1640，37℃培养3天。收集细胞，荧光定量RT-PCR检测病毒核酸含量。采用相对定量方法(2-ΔΔCt)进行分析。检测病毒核酸所使用的引物为：上游引物：5’-GTGAGATCTTACTGCTATGAG-3’；下游引物：5’-ACTTGGCACATGTCTGTATGC-3’。内参选用GAPDH基因，上游引物：5’-ACTTGGCACATGTCTGTATGC-3’；下游引物：5’-CACCAGCATCACCCCATTT-3’。
实施结果：抗原蛋白免疫组雏鸭血清中坦布苏病毒的含量显著高于对照组(大于104倍)，且病毒血症持续时间长于对照组(图2)。
序列表
<110> 江苏省农业科学院
<120> 引起坦布苏病毒抗体依赖增强作用的抗原的应用
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Ser Met Thr Phe Leu Ala Val Gly Gly Ile Leu Val Phe Leu Ala
1 5 10 15
<210> 2
<211> 45
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 2
tctatgactt ttctagctgt aggaggaatt ttagtcttcc tggca 45
Claims (6)
1.一种引起坦布苏病毒抗体依赖增强作用的抗原在制备坦布苏病毒疫苗中的应用；所述的引起坦布苏病毒抗体依赖增强作用的抗原，其氨基酸序列如SEQ ID NO.1所示。
2.一种引起坦布苏病毒抗体依赖增强作用的抗原在制备坦布苏病毒检测试剂中的应用；所述的引起坦布苏病毒抗体依赖增强作用的抗原，其氨基酸序列如SEQ ID NO.1所示。
3.编码SEQ ID NO.1所示的引起坦布苏病毒抗体依赖增强作用的抗原的基因在制备坦布苏病毒疫苗中的应用。
4.根据权利要求3所述的应用，其特征在于所述的基因其核苷酸序列如SEQ ID NO.2所示。
5.编码SEQ ID NO.1所示的引起坦布苏病毒抗体依赖增强作用的抗原的基因在制备坦布苏病毒检测试剂中的应用。
6.根据权利要求5所述的应用，其特征在于所述的基因其核苷酸序列如SEQ ID NO.2所示。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810499820.8A CN108676078B (zh) | 2018-05-23 | 2018-05-23 | 引起坦布苏病毒抗体依赖增强作用的抗原的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810499820.8A CN108676078B (zh) | 2018-05-23 | 2018-05-23 | 引起坦布苏病毒抗体依赖增强作用的抗原的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108676078A true CN108676078A (zh) | 2018-10-19 |
| CN108676078B CN108676078B (zh) | 2021-04-20 |
Family
ID=63808023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810499820.8A Active CN108676078B (zh) | 2018-05-23 | 2018-05-23 | 引起坦布苏病毒抗体依赖增强作用的抗原的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108676078B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110128524A (zh) * | 2019-06-04 | 2019-08-16 | 中国农业科学院兰州兽医研究所 | 猪IgA+ B细胞类别转换标志物序列及检测方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102533668A (zh) * | 2010-12-20 | 2012-07-04 | 中国农业科学院上海兽医研究所 | 一种鸭黄病毒及其疫苗、试剂盒 |
| CN102977194A (zh) * | 2012-11-22 | 2013-03-20 | 青岛宝依特生物制药有限公司 | 一种鸭坦布苏病毒e蛋白基因及其应用 |
| CN102993300A (zh) * | 2012-11-22 | 2013-03-27 | 青岛宝依特生物制药有限公司 | 鸭坦布苏病毒多克隆抗体及其制备方法 |
| CN104280551A (zh) * | 2013-07-11 | 2015-01-14 | 中国农业科学院哈尔滨兽医研究所 | 鸭坦布苏病毒病e-elisa检测试剂盒及其制备方法 |
| CN104610455A (zh) * | 2014-10-20 | 2015-05-13 | 青岛农业大学 | 一种鸭坦布苏病毒基因工程亚单位疫苗 |
-
2018
- 2018-05-23 CN CN201810499820.8A patent/CN108676078B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102533668A (zh) * | 2010-12-20 | 2012-07-04 | 中国农业科学院上海兽医研究所 | 一种鸭黄病毒及其疫苗、试剂盒 |
| CN102977194A (zh) * | 2012-11-22 | 2013-03-20 | 青岛宝依特生物制药有限公司 | 一种鸭坦布苏病毒e蛋白基因及其应用 |
| CN102993300A (zh) * | 2012-11-22 | 2013-03-27 | 青岛宝依特生物制药有限公司 | 鸭坦布苏病毒多克隆抗体及其制备方法 |
| CN104280551A (zh) * | 2013-07-11 | 2015-01-14 | 中国农业科学院哈尔滨兽医研究所 | 鸭坦布苏病毒病e-elisa检测试剂盒及其制备方法 |
| CN104610455A (zh) * | 2014-10-20 | 2015-05-13 | 青岛农业大学 | 一种鸭坦布苏病毒基因工程亚单位疫苗 |
Non-Patent Citations (6)
| Title |
|---|
| K HAN等: "Generation and characterization of a monoclonal antibody against duck Tembusu virus envelope protein", 《POL J VET SCI》 * |
| 仇华吉: "《猪生殖-呼吸道综合征》", 31 May 2000 * |
| 余磊: "鸭坦布苏病毒E蛋白抗原性分析", 《中国优秀硕士学位论文全文数据库（电子期刊）》 * |
| 张琳: "鸭坦布苏病毒E蛋白抗原表位的鉴定", 《中国优秀硕士学位论文全文数据库（电子期刊）》 * |
| 薛强: "病毒感染的抗体依赖性增强作用及其机制", 《中国预防兽医学报》 * |
| 韩凯凯等: "鸭坦布苏病毒囊膜蛋白抗原表位的串联表达与抗原性", 《江苏农业学报》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110128524A (zh) * | 2019-06-04 | 2019-08-16 | 中国农业科学院兰州兽医研究所 | 猪IgA+ B细胞类别转换标志物序列及检测方法 |
| CN110128524B (zh) * | 2019-06-04 | 2021-05-07 | 中国农业科学院兰州兽医研究所 | 猪IgA+ B细胞类别转换标志物序列及检测方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108676078B (zh) | 2021-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6957580B2 (ja) | 新規多価ナノ粒子に基づくワクチン | |
| JP2002531415A (ja) | ペプチドベースのインフルエンザ用ワクチン | |
| JP2023511444A (ja) | 安定化されたｎａを有する組換えインフルエンザウイルス | |
| US5882650A (en) | Cross-reactive influenza A immunization | |
| CN108697786B (zh) | 含有固定化病毒粒子的疫苗 | |
| WO2013075266A1 (en) | Immune methods against influenza viruses and combinatorial vaccines thereof | |
| CN111647087B (zh) | 一种嵌合病毒样颗粒疫苗及其制备方法和应用 | |
| CN106520710A (zh) | 表达鸭坦布苏病毒prm和E蛋白重组新城疫病毒活载体疫苗的制备及应用 | |
| WO2011134163A1 (zh) | 一种h9n2亚型禽流感灭活疫苗的制备方法及产品 | |
| CN102127554A (zh) | 一种日本脑炎颗粒疫苗及其制备方法和应用 | |
| CN108676078B (zh) | 引起坦布苏病毒抗体依赖增强作用的抗原的应用 | |
| CN115340609A (zh) | 一种口蹄疫病毒多抗原表位融合蛋白、蛋白笼纳米颗粒及其制备方法 | |
| RU2660566C2 (ru) | Иммунизация вектором на основе вируса бешенства, экспрессирующим чужеродный белковый антиген | |
| CN104073470A (zh) | 一种h9n2亚型禽流感病毒的转瓶培养方法 | |
| CN110386965B (zh) | 一种坦布苏病毒e蛋白b细胞表位及其编码基因和应用 | |
| CN117815377A (zh) | mRNA的用途 | |
| KR102529010B1 (ko) | 조작된 인플루엔자 헤마글루티닌 폴리펩티드의 변형 | |
| CN102603898B (zh) | 与i群禽腺病毒免疫相关融合蛋白及其编码基因与应用 | |
| CN109705194B (zh) | 一种促进aiv和/或ndv疫苗的免疫反应的法氏囊活性五肽及应用 | |
| CN115697398A (zh) | 包含两种不同rna复制子颗粒的甲型猪流感病毒疫苗 | |
| Li et al. | Protective effects of a novel chimeric virus–like particle vaccine against virulent NDV and IBDV challenge | |
| WO2020147015A1 (zh) | 口蹄疫病毒样颗粒抗原、及其疫苗组合物、制备方法和应用 | |
| CN118420773A (zh) | 一种重组蛋白纳米颗粒及其制备方法和在制备广谱抗流感病毒疫苗中的应用 | |
| CN118726484A (zh) | ILTV gD蛋白抗原表位表达盒及重组病毒和应用 | |
| CN105664151B (zh) | 一种禽网状内皮增生症病毒亚单位疫苗注射复合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |